An executive at a $12 billion biotech startup said it’s possible the company will go public in the next 3-4 years

Samumed CEO Osman Kibar, CFO Cevdet Samikoglu, and chief medical officer Yusuf Yazici Diana Yukari/Business Insider; photos courtesy Samumed


Samumed, a private company that’s racked up a heady valuation of $12 billion, has a potential timeline for when it might go public.

It’s possible the company could go public over the next three to four years, Samumed’s chief business officer Erich Horsley said at the UBS Global Healthcare conference on Monday in New York.

The company has already raised $300 million from backers including high-net-worth individuals and sovereign funds rather than a roster of venture capitalists.

Click Here To Read More […]

Annually.com is Available for Purchase. Learn more by clicking the button here:

Get More Info